CRIS Current Research Information System

RONDONI, MICHELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.218
NA - Nord America 3.470
EU - Europa 3.262
SA - Sud America 220
AF - Africa 209
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 3
Totale 11.400
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.422
VN - Vietnam 1.317
IT - Italia 1.066
CN - Cina 1.057
SG - Singapore 964
GB - Regno Unito 642
SE - Svezia 339
DE - Germania 311
HK - Hong Kong 271
FR - Francia 182
BR - Brasile 156
IN - India 151
JP - Giappone 134
UA - Ucraina 125
NL - Olanda 120
RU - Federazione Russa 119
KR - Corea 116
IE - Irlanda 84
CI - Costa d'Avorio 69
FI - Finlandia 62
TG - Togo 54
ZA - Sudafrica 51
EE - Estonia 40
CH - Svizzera 35
CA - Canada 28
JO - Giordania 27
AR - Argentina 26
BD - Bangladesh 24
BE - Belgio 21
BG - Bulgaria 21
PL - Polonia 21
ID - Indonesia 20
ES - Italia 19
IQ - Iraq 18
PH - Filippine 18
TH - Thailandia 18
TW - Taiwan 18
EU - Europa 15
SC - Seychelles 14
GR - Grecia 13
MX - Messico 13
EC - Ecuador 11
IR - Iran 10
SA - Arabia Saudita 9
TR - Turchia 9
AT - Austria 7
PK - Pakistan 7
PY - Paraguay 7
CL - Cile 6
MY - Malesia 6
NG - Nigeria 6
RO - Romania 6
CZ - Repubblica Ceca 5
LB - Libano 5
LT - Lituania 5
AE - Emirati Arabi Uniti 4
PT - Portogallo 4
VE - Venezuela 4
BY - Bielorussia 3
CO - Colombia 3
CR - Costa Rica 3
KE - Kenya 3
KZ - Kazakistan 3
NP - Nepal 3
SK - Slovacchia (Repubblica Slovacca) 3
UZ - Uzbekistan 3
BA - Bosnia-Erzegovina 2
EG - Egitto 2
GY - Guiana 2
IL - Israele 2
MN - Mongolia 2
NE - Niger 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PE - Perù 2
TN - Tunisia 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
BO - Bolivia 1
DM - Dominica 1
DZ - Algeria 1
ET - Etiopia 1
GH - Ghana 1
HR - Croazia 1
HU - Ungheria 1
MA - Marocco 1
MM - Myanmar 1
MR - Mauritania 1
MT - Malta 1
RS - Serbia 1
TT - Trinidad e Tobago 1
Totale 11.400
Salva come PNG Salva come JPEG
Città #
Singapore 669
Southend 557
Ho Chi Minh City 352
Ashburn 334
Fairfield 309
Chandler 288
Hanoi 269
Hong Kong 251
Hefei 250
San Jose 178
Wilmington 168
Houston 161
Woodbridge 150
Seattle 143
Dong Ket 130
Beijing 127
Tokyo 123
Cambridge 122
Ann Arbor 120
Santa Clara 113
Princeton 105
Seoul 99
Bologna 97
Milan 88
Dublin 83
Dallas 81
Jacksonville 81
Boardman 80
Abidjan 69
Los Angeles 67
Lauterbourg 65
Florence 64
Padova 56
Lomé 54
New York 53
Turin 50
Westminster 50
Nanjing 49
Rome 44
Haiphong 42
Helsinki 42
Da Nang 32
Saint Petersburg 32
Council Bluffs 30
Shenyang 28
Berlin 27
Buffalo 27
Amman 26
Frankfurt am Main 26
Jinan 25
Munich 25
Ha Long 24
Bern 23
Biên Hòa 23
Bengaluru 21
Redondo Beach 21
Nanchang 20
Hebei 19
Medford 19
Naples 19
San Diego 18
Shanghai 18
Sofia 18
São Paulo 18
Bremen 17
Brussels 17
Changsha 17
Pavia 17
Orem 16
Falls Church 15
Hải Dương 15
Thái Nguyên 15
Warsaw 15
Zhengzhou 15
Ninh Bình 14
Redmond 14
Toronto 14
Guangzhou 13
Jiaxing 13
Haikou 12
Verona 12
Chicago 11
Mülheim 11
Norwalk 11
Quận Bình Thạnh 11
Vũng Tàu 11
Baghdad 10
Catania 10
Düsseldorf 10
Lappeenranta 10
Palermo 10
Pescara 10
Brooklyn 9
Can Tho 9
Jakarta 9
Johannesburg 9
London 9
Mahé 9
Mountain View 9
Nuremberg 9
Totale 7.210
Salva come PNG Salva come JPEG
Nome #
Instillazione diretta intranasale di amfotericina B liposomiale nella terapia delle micosi nasali. 823
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 656
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 300
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 290
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 217
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 211
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 209
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 207
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 206
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 206
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 201
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 198
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 194
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 191
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 176
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 176
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 171
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 171
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 169
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 168
Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions 167
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 167
Ultra-Deep Sequencing (UDS) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 166
Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells 164
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 163
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 162
Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia 162
Leucemia mieloide cronica: terapia molecolare 159
Advanced mast cell disease: an Italian Hematological Multicenter experience 158
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 158
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients 157
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 153
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 151
Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely. 149
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 148
Novel insights and therapeutic approaches in secondary AML 144
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study. 142
PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. 141
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 141
WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. 141
Acute Myeloid Leukemia: Updates on Diagnosis, Treatment and Management 139
High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL) 137
Soft tissue and skeletal involvement in FIP1L1-PDGFR-A positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission 136
A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis 134
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 132
HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING IDENTIFIES NOVEL UNIPARENTAL DISOMY AND FOCAL COPY NUMBER ALTERATIONS IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) 128
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 128
New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders 124
Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant) 122
Imatinib mesylate in the treatment of hematologic malignancies. 122
The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors. 122
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis 122
Hypereosinophilic syndrome and molecularly targeted therapy. 121
Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. 121
Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype 120
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain 114
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience 112
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. 110
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly 109
Strategies in the treatment of acute myeloid leukemia. 106
null 104
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 100
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study 99
Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients. 98
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. 90
Rearrangements of ATP5L‐KMT2A in acute lymphoblastic leukaemia 78
null 76
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 73
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation 52
Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series 45
The Italian Mastocytosis Registry: 6-year experience from a Hospital-Based Registry 42
Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study 41
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351 21
Totale 11.611
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.616
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.616
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021327 0 0 0 0 0 0 0 0 0 54 37 236
2021/20221.006 94 17 63 117 94 84 17 66 37 75 187 155
2022/20231.365 160 233 52 173 66 96 50 65 224 28 171 47
2023/2024548 29 63 37 42 44 126 43 60 23 26 28 27
2024/20251.634 64 221 120 108 204 84 185 69 27 148 100 304
2025/20264.194 393 911 387 314 393 230 315 139 794 318 0 0
Totale 11.611